JP2025502300A5 - - Google Patents
Info
- Publication number
- JP2025502300A5 JP2025502300A5 JP2024542125A JP2024542125A JP2025502300A5 JP 2025502300 A5 JP2025502300 A5 JP 2025502300A5 JP 2024542125 A JP2024542125 A JP 2024542125A JP 2024542125 A JP2024542125 A JP 2024542125A JP 2025502300 A5 JP2025502300 A5 JP 2025502300A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- crystalline form
- salt
- degrees
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22151820.2 | 2022-01-17 | ||
| EP22151820 | 2022-01-17 | ||
| EP22170332.5 | 2022-04-27 | ||
| EP22170332 | 2022-04-27 | ||
| PCT/EP2023/050883 WO2023135303A1 (en) | 2022-01-17 | 2023-01-16 | Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025502300A JP2025502300A (ja) | 2025-01-24 |
| JP2025502300A5 true JP2025502300A5 (enExample) | 2025-12-09 |
Family
ID=84982261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024542125A Pending JP2025502300A (ja) | 2022-01-17 | 2023-01-16 | ヘリカーゼプリマーゼ阻害剤の固体結晶形態及びその製造方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20250115565A1 (enExample) |
| EP (1) | EP4466255A1 (enExample) |
| JP (1) | JP2025502300A (enExample) |
| KR (1) | KR20240134979A (enExample) |
| AU (1) | AU2023206628A1 (enExample) |
| CA (1) | CA3246779A1 (enExample) |
| CL (1) | CL2024002124A1 (enExample) |
| IL (1) | IL314188A (enExample) |
| MX (1) | MX2024008821A (enExample) |
| PY (1) | PY2302301A (enExample) |
| TW (1) | TW202337444A (enExample) |
| UY (1) | UY40111A (enExample) |
| WO (1) | WO2023135303A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3265860A1 (en) * | 2022-08-29 | 2024-03-07 | Assembly Biosciences, Inc. | Pharmaceutical compositions against the herpes virus |
| CN121532378A (zh) | 2023-07-17 | 2026-02-13 | 创新分子股份有限公司 | 抗病毒解旋酶-引发酶抑制剂化合物的微粉化结晶盐酸盐 |
| WO2026078039A1 (en) | 2024-10-09 | 2026-04-16 | Innovative Molecules Gmbh | Oral administration forms of antiviral helicase-primase inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2000000109A (es) | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| DE10131128A1 (de) | 2001-06-28 | 2003-01-16 | Bayer Ag | Sekundäre Sulfonamide |
| GEP20207128B (en) | 2016-04-06 | 2020-07-10 | Molecules Gm Innovative | Aminothiazole derivatives useful as antiviral agents |
| DK3692039T3 (da) | 2017-10-05 | 2023-03-13 | Innovative Molecules Gmbh | Enantiomerer af substituerede thiazoler som antivirale forbindelser |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| MX2023004955A (es) | 2020-10-29 | 2023-05-17 | Innovative Molecules Gmbh | Compuestos de aminotiazol deuterados como compuestos antiviricos. |
-
2023
- 2023-01-16 IL IL314188A patent/IL314188A/en unknown
- 2023-01-16 KR KR1020247027250A patent/KR20240134979A/ko active Pending
- 2023-01-16 WO PCT/EP2023/050883 patent/WO2023135303A1/en not_active Ceased
- 2023-01-16 EP EP23700877.6A patent/EP4466255A1/en active Pending
- 2023-01-16 US US18/729,411 patent/US20250115565A1/en active Pending
- 2023-01-16 UY UY0001040111A patent/UY40111A/es unknown
- 2023-01-16 MX MX2024008821A patent/MX2024008821A/es unknown
- 2023-01-16 TW TW112101829A patent/TW202337444A/zh unknown
- 2023-01-16 PY PY202302302301A patent/PY2302301A/es unknown
- 2023-01-16 AU AU2023206628A patent/AU2023206628A1/en active Pending
- 2023-01-16 CA CA3246779A patent/CA3246779A1/en active Pending
- 2023-01-16 JP JP2024542125A patent/JP2025502300A/ja active Pending
-
2024
- 2024-07-15 CL CL2024002124A patent/CL2024002124A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017527578A5 (enExample) | ||
| JP2007505108A5 (enExample) | ||
| US20100286081A1 (en) | 5-amino-3-(2',3'-di-o-acetyl-beta-d-ribofuranosyl)-3h-thiazolo[4,5-d] pyrimidin-2-oce salts and crystalline forms | |
| ES2466221T3 (es) | Monohidrato de mesilato de N-[5-aminosulfonil)-4-metil-1,3-tiazol-2-il]-N-metil-2-[4-(2-piridinil)fenil]acetamida | |
| JP2024534014A5 (enExample) | ||
| JP2017504591A5 (enExample) | ||
| JP2005509632A5 (enExample) | ||
| JP2022523368A5 (enExample) | ||
| JP2024521412A5 (enExample) | ||
| JP2024520630A5 (enExample) | ||
| JP2024534517A5 (enExample) | ||
| JP2024547113A5 (enExample) | ||
| WO2022189599A1 (en) | Crystalline forms of mavacamten for the treatment of hcm | |
| TW200404802A (en) | Xanthine phosphodiesterase V inhibitor polymorphs | |
| JP2022553833A5 (enExample) | ||
| JP2024524701A5 (enExample) | ||
| CA2528192A1 (en) | Cristalline ziprasidone hcl and processes for preparation thereof | |
| US20240051964A1 (en) | Solid state forms of capivasertib and process for preparation thereof | |
| RU2012127777A (ru) | Лекарственные формы, соли и полиморфы транснорсертралина и их применение | |
| JP2025508792A5 (enExample) | ||
| CN118302412A (zh) | Nirogacestat盐的固态形式 | |
| JP2011504890A5 (enExample) | ||
| JP2024542840A5 (enExample) | ||
| US12441701B2 (en) | Solid state forms of roluperidone and salts thereof | |
| WO2014135834A1 (en) | Oxalic acid addition salts and/or solvates of a selective estrogen receptor modulator |